The FDA approved a new drug this week for advanced pancreatic cancer, and the people living with the disease are the ones being asked to carry the risk, the hope, and the wait. The drug, daraxonrasib, nearly doubled survival time for patients and had fewer severe side effects than other treatments, according to PBS NewsHour. Pancreatic cancer has long been one of the deadliest types of cancer, with a five-year overall survival rate of just 13 percent.
Who Gets the Relief
Dr. Robert Vonderheide, who directs the Abramson Center at Penn Medicine and is the president-elect of the American Association for Cancer Research, said, “I think we have only seen the beginning.” He said the FDA approved the drug for patients with advanced pancreatic cancer, doubling their survival and “really offering incredible hope and excitement for our patients and their families.” That hope arrives through a gate kept by regulators and the medical-industrial apparatus, with access still defined by who qualifies, when they qualify, and how far the disease has already advanced.
Vonderheide said the opportunity now exists to bring the drug to patients in earlier stages or just after diagnosis. That’s the familiar reform script: a breakthrough appears, then the system decides how slowly to widen the door. For now, the approval sits inside the same hierarchy that controls who gets treatment, when, and under what terms.
The Chemistry and the Gatekeepers
Vonderheide said the treatment targets the RAS oncogene, which he called “the mutated engine that drives pancreatic cancer and many other tumor types as well,” and said it has been very difficult to drug and block with conventional chemistry. He said, “What’s happened here is a brand-new type of chemistry, really unprecedented. We call it molecular glue that gums up this mutated engine room as it spins on a flywheel, just bringing it to a halt.” He said basic chemistry and basic research made the new approach possible.
That basic research doesn’t happen by magic. It comes from institutions, labs, and funding streams that decide which suffering gets attention and which doesn’t. The result here is a drug that may help some patients facing one of the deadliest cancers, but only after years of work inside a system that parcels out life-saving tools one approval at a time.
PBS also reported on a new individualized vaccine that helps people with melanoma, a type of skin cancer, live longer. Vonderheide said the news was announced by the companies involved in building the mRNA vaccine, and that their clinical trial had a positive result. He said it’s not yet FDA-approved. The patients were in remission but at risk for relapse, and the vaccine lowered the chances of relapse by generating a T-cell immune response against the mutations found in the tumors themselves.
What the Companies Announced
Vonderheide said the full data report from the companies is still to come, and he said researchers are looking for two things: the magnitude of the effect and whether the vaccine works as designed. He said they want to know how much survival has been impacted and increased, and whether the immune response can be mobilized to an even greater extent with improvements to the vaccine. The language is clinical, but the stakes are plain. People in remission are still being measured against relapse, while the companies and researchers sort through the numbers.
He said, “A hundred percent. This is the first of what I think will be a wave of cancer vaccines, lowering the chance of relapse, recurrence, perhaps one day even preventing certain types of cancer from ever appearing at all.” He said the immune system has been harnessed safely over the last 10 years, and that the news this week was exciting.
Vonderheide also addressed concerns about mRNA technology. He said mRNA vaccines were first developed for the COVID pandemic, that hundreds of millions of individuals received that vaccine with detailed safety data, and that mRNA is highly effective not just against COVID, but also against influenza and perhaps cancer. He said, “The power of mRNA as a medicine, whether as a vaccine or in other ways, is unprecedented. It’s before us.”
The promise is real enough in the numbers PBS reported. So is the structure around it. Patients face advanced disease, remission, relapse, and the long wait for approval, while institutions and companies announce progress from above and call it hope.